Workflow
康哲药业午前涨超4% 创新药口服小分子JAK1抑制剂Povorcitinib获批准开展临床试验

Core Viewpoint - 康哲药业's stock price increased by over 4% in the morning session, currently trading at 13.59 HKD with a transaction volume of 66.4 million HKD, following the announcement of clinical trial approvals for its drug povorcitinib [1] Group 1: Company Developments - 康哲药业's subsidiary, 德镁医药有限公司, is applying for an independent listing on the Hong Kong Stock Exchange [1] - The company received a clinical trial approval notice from the National Medical Products Administration (NMPA) of China for povorcitinib on August 28, 2025 [1] - NMPA has approved clinical trials for povorcitinib targeting non-segmental vitiligo and moderate to severe hidradenitis suppurativa (HS) [1] Group 2: Product Information - Povorcitinib is a selective oral small molecule JAK1 inhibitor, with substance and use patents in specific countries/regions [1] - The drug is currently undergoing Phase 3 clinical trials for non-segmental vitiligo, HS, and nodular prurigo in several overseas countries [1] - Additionally, Phase 2 clinical trials for asthma and chronic spontaneous urticaria are also in progress [1]